bortezomib

P3, N=177, Active, not recruiting, University of Arkansas | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027

P3, N=90, Recruiting, Sinocelltech Ltd.

P3, N=662, Active, not recruiting, University of Heidelberg Medical Center | Trial completion date: Mar 2027 --> Jun 2028 | Trial primary completion date: May 2025 --> Jun 2028

Rescue experiments and bortezomib intervention experiments further confirmed that FBP1 is essential for mediating the oncogenic effects of TRIM47 in HCC progression. To explore its therapeutic potential, TRIM47 siRNA was developed and loaded into poly (lactic acid)-DC-Chol nanoparticles (siTRIM47@PD NPs), which significantly reduced tumor growth and metastasis in an orthotopic HCC animal model, highlighting the potential of TRIM47 as a therapeutic target. Together, these findings underscore the pivotal role of TRIM47 in HCC progression through FBP1-mediated regulation of energy metabolism, and highlight siRNA-based TRIM47 targeting as a promising approach to improve HCC treatment outcomes.

P2, N=29, Recruiting, Seoul National University Hospital | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: May 2026 --> Dec 2027

Moreover, in vivo studies in MOC2-induced tumor-bearing mice demonstrated a significant upregulation of ER stress markers, including PERK and PDI, as well as remodeling of macrophages, characterized by the upregulation of M1 markers, such as iNOS, TNF-α, and CD86. Thus, BTZ@GOT is an efficient nanotherapy that warrants further exploration for the treatment of oral carcinoma.

Triplet regimens that include an immunomodulatory agent, proteasome inhibitor, and dexamethasone are widely used in newly diagnosed and relapsed/refractory (R/R) multiple myeloma (MM)...Additionally, we have compared these results with similar combinations with the immunomodulatory agent pomalidomide (POM). Our studies indicate that the MEZI/BTZ/DEX triplet is superior to all single agents and POM/BTZ/DEX in terms of potency of antiproliferative and proapoptotic activities, substrate degradation depth and kinetics in the presence of BTZ, and in vivo efficacy. We show that the combination of MEZI with BTZ increases cell death through disruption of multiple phases of the cell cycle and this thereby enhances the direct cytotoxic effects of the combination treatment.

P=N/A, N=12, Not yet recruiting, Zhejiang Xiaoshan Hospital; Hainan Dermavon Pharmaceutical Technology Co., Ltd.

P4, N=117, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital

SRT-1720 induces oxidative stress and apoptosis in leukemic lymphocytes through SIRT1-independent pathway(s). In contrast, it enhances antioxidant defense in normal lymphocytes through a SIRT1-dependent pathway. These findings highlight the potential of SRT-1720 as an adjuvant to chemotherapy in T-ALL, particularly in drug combinations demonstrating strong synergism, which may allow dose reduction and decreased toxicity.

The combination of rosuvastatin and bortezomib exerts a synergistic effect by inhibiting CCL3, thereby rebalancing bone remodeling and promoting osteogenesis. This strategy represents a promising novel therapeutic approach for mitigating MBD.

P3, N=292, Recruiting, Sinocelltech Ltd. | Not yet recruiting --> Recruiting